Amylyx Pharmaceuticals, Inc. Stock News

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the qua

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best op

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.

Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to b

Vertex Pharmaceuticals' cystic fibrosis franchise is successful, but it's also running out of room to grow. Expected results from a trial with an experimental pain reliever called VX-548 could push Ve

Amylyx Therapeutics shares have limited downside ahead of a Phase 3 trial of Relyvrio, an ALS treatment candidate, according to Baird. Analysts have initiated coverage on the stock with an Outperform

Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive

Investing in biotech stocks is not for risk-averse investors. However, if you're an investor who is serious about generating outsized gains, it's a sector that you can't overlook.

Amylyx Pharmaceuticals is a biotech company that develops treatments for neurodegenerative diseases, with its product AMX0035 approved by the FDA for ALS therapy. The company's Phase III clinical tria

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Josh Cohen - C

Amylyx Pharmaceuticals shares fell Friday after its ALS (amyotrophic lateral sclerosis) drug was denied marketing authorization by European Union regulators for the second time.  The repeat rebuff co

Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on Albrioza, a treatment for amyot